FDA Makes Nizoral Tablets 2nd-Line Treatment Due To Liver, Adrenal Risks

FDA Makes Nizoral Tablets 2nd-Line Treatment Due To Liver, Adrenal Risks

SILVER SPRING, Md. - The Food and Drug Administration on July 26 said that Nizoral brand ketoconazole tablets should not be a first-line treatment for fungal infections because it can cause severe liver injury and adrenal gland problems or have harmful interactions with other drugs.

Find full version on lexis Advance®
Access this news story on lexis.com®